ECM
NVO

ETrade Capital Management’s Novo Nordisk NVO Stock Holding History

ETrade Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$3.84M Sell
110,732
-30,594
-22% -$1.02M 0.07% 139
2020
Q2 		$4.63M Buy
141,326
+76,228
+117% +$2.43M 0.1% 105
2020
Q1 		$1.96M Sell
65,098
-6,552
-9% -$195K 0.05% 197
2019
Q4 		$2.07M Buy
71,650
+24
+0% +$665 0.05% 208
2019
Q3 		$1.85M Buy
71,626
+12,354
+21% +$312K 0.05% 219
2019
Q2 		$1.51M Buy
59,272
+1,372
+2% +$33.9K 0.04% 256
2019
Q1 		$1.51M Buy
57,900
+4,412
+8% +$108K 0.04% 240
2018
Q4 		$1.23M Buy
53,488
+2,638
+5% +$58.6K 0.04% 246
2018
Q3 		$1.2M Buy
50,850
+41,242
+429% +$1.01M 0.03% 315
2018
Q2 		$222K Sell
9,608
-23,708
-71% -$563K 0.01% 735
2018
Q1 		$820K Buy
33,316
+4,994
+18% +$131K 0.03% 397
2017
Q4 		$760K Buy
28,322
+3,116
+12% +$79.2K 0.02% 405
2017
Q3 		$607K Buy
25,206
+12,946
+106% +$293K 0.02% 421
2017
Q2 		$263K Sell
12,260
-79,200
-87% -$1.6M 0.01% 606
2017
Q1 		$1.57M Buy
91,460
+9,702
+12% +$169K 0.06% 179
2016
Q4 		$1.47M Sell
81,758
-1,336
-2% -$24.2K 0.07% 164
2016
Q3 		$1.73M Sell
83,094
-4,906
-6% -$122K 0.08% 148
2016
Q2 		$2.37M Buy
88,000
+168
+0.2% +$4.61K 0.13% 96
2016
Q1 		$2.38M Sell
87,832
-4,770
-5% -$128K 0.14% 81
2015
Q4 		$2.69M Sell
92,602
-5,170
-5% -$143K 0.16% 68
2015
Q3 		$2.65M Buy
97,772
+3,410
+4% +$96.5K 0.16% 68
2015
Q2 		$2.58M Sell
94,362
-1,098
-1% -$30.9K 0.15% 75
2015
Q1 		$2.55M Buy
95,460
+2,870
+3% +$66.1K 0.15% 79
2014
Q4 		$1.96M Buy
92,590
+1,644
+2% +$36.7K 0.12% 117
2014
Q3 		$2.17M Buy
90,946
+5,284
+6% +$122K 0.14% 77
2014
Q2 		$1.98M Buy
85,662
+7,338
+9% +$162K 0.13% 105
2014
Q1 		$1.79M Sell
78,324
-13,786
-15% -$294K 0.13% 104
2013
Q4 		$1.7M Buy
92,110
+16,090
+21% +$280K 0.13% 88
2013
Q3 		$1.29M Buy
76,020
+14,950
+24% +$251K 0.12% 98
2013
Q2 		$946K Buy
+61,070
New +$1.02M 0.1% 99

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

ETrade Capital Management's NVO Position: Q3 2020 in Review

ETrade Capital Management reduced its Novo Nordisk (NVO) stake by 22% in Q3 2020, selling an estimated $1.02M and leaving 110,732 shares worth $3.84M. The position accounts for 0.07% of the portfolio, ranked #139.

ETrade Capital Management first reported a position in NVO in Q2 2013 and has held it in 30 quarters since. The position peaked at $4.63M in Q2 2020. 660 funds tracked by Wall St. Rank hold NVO as of Q3 2020.

  • ETrade Capital Management held 110,732 shares of Novo Nordisk worth $3.84M as of Q3 2020.
  • ETrade Capital Management sold 30,594 Novo Nordisk shares in Q3 2020, an estimated $1.02M.
  • Novo Nordisk made up 0.07% of ETrade Capital Management's portfolio in Q3 2020, its #139 holding.
  • ETrade Capital Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 30 quarters since.
  • ETrade Capital Management's Novo Nordisk position peaked at $4.63M in Q2 2020.
  • 660 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.